Clearbridge BioMedics’ mission is to innovate and develop novel medical research tools and diagnostic products using cutting-edge technologies, in order to catalyse medical research and discovery, revolutionise disease management, and advance patient care.
Clearbridge Biomedics (CBB) specialises in novel platforms with applications in oncology research and diagnostics. It is a spin-off from National University of Singapore (NUS) and is also the first incubatee of Clearbridge Accelerator, a Singapore Government (National Research Foundation) backed high-technology incubator. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America.
Leveraging on novel microfluidic technologies, the ClearCell® Systems and CTChip® adopt a label-free approach for effective detection and isolation of wholly intact Circulating Tumour Cells (CTCs) from patients` blood samples for early cancer diagnosis. Cancer is one of the most important healthcare challenges in the 21st century, more than 12 million new cases are diagnosed each year, and is also responsible for 7.5 million deaths every year. However, cancer diagnosis is not terminal, and can be managed, or even cured, by today’s therapies if it is detected early, and appropriate action is taken. Cancer deaths mainly occur in solid tumour cancers when the cancer spreads from the primary tumour to the other organs, a process known as Metastasis. CTCs, the carrier of metastasis, are extremely rare cancer cells that have detached from a primary tumour and are circulating in the bloodstream. Capturing and analysing CTCs could thus enable clinicians to conduct cancer screening, diagnosis and post-cancer monitoring that will be invaluable in allowing clinicians to make timely and life-saving decisions. The use of CTCs in a rapid, point-of-care liquid biopsy will pave the way to improved cancer detection assays, and improve the cancer management process. Most impressively, the ClearCell® Systems are able to capture and retrieve these CTCs, allowing researchers to conduct critical genetic analysis to optimise cancer therapies, paving the way for personalised cancer treatment. The ClearCell® Systems aim to be the next generation of non-invasive “liquid biopsy” approach for cancer screening, diagnosis, staging, personalised medicine, and treatment monitoring.